Cash on hand is what can get them through to the September...

Cash on hand is what can get them through to the September quarter
That doesn’t include what international sales could begin to produce
In the latest investor conference call, they actually state if all the options were exercised then they may not need to raise again
Stephen has a history of under promising and over delivering, and this December quarter could be another case of just that
Their recurring revenue growth is undeniable and with another partner on board from the GMAC like Menicon & Oculus, the growth will continue to flourish
Myopia is only in the beginning stages of ramping up its awareness and there are some massive companies looking to capitalise on this pandemic
Johnson & Johnson and Alcon don’t have contact lenses of their own for Myopia progression, but we’re some of the main sponsors at the most recent inaugural symposium which Dr Snowdy presented our data at
Dont be surprised to see a tie up with one of these majors moving forward to compete with Coopervision for a slice of the multi billion dollar pie in the US
Supplying these conglomerates with our lenses is the ideal situation for a small company like VTI as they will be the ones who can dominate the space at the end of the day
Solid future ahead for Visioneering after all the years of hard work developing the best product in the market for Myopia, is about to really begin paying off